Is There FDA Approval for Migraines? | Magna Wave PEMF

Is There FDA Approval for PEMF Therapy for Migraines?

596 442 Magna Wave PEMF
Is There FDA Approval for PEMF Therapy for Migraines?

Is There FDA Approval for PEMF Therapy for Migraines?

The first thing you should know when it comes to PEMF therapy, and how it may be beneficial to your wellness, is that Magna Wave PEMF doesn’t treat any indications or conditions. Magna Wave PEMF does provide sessions to the body via energy supplementation, as a result of pulsed electromagnetic field therapy, to allow the body to be in a better position to heal itself. As the only PEMF device tested by the FDA, Magna Wave was recently asked “Is there FDA approval for Migraines?” Pat Ziemer, CEO of Magna Wave PEMF, elaborates in this Q & A.

Is there FDA approval for migraines?

No, there is not FDA approval for migraines. While there are many approvals from the FDA, or clearances, for the PEMF modality, FDA approval for migraines is not one of them. There are people that use Magna Wave machines for migraines, but there is no FDA approval for migraines specifically. Magna Wave machines are considered off-the-shelf non-invasive wellness devices and that’s how they are used.

1-month follow-up. All continued to report decreased headache activity: 50% Good, 38% Excellent

Study, Study, Study

While there is no FDA approval for migraines, there is some data available from studies utilizing pulsed electromagnetic field therapy. In a double-blind, placebo-controlled study on the effects of PEMF on Migraines, 34 women and 8 men were evaluated who met the criteria for migraine based on the International Headache Society’s standards.

Each individual kept a 1-month baseline log, pre-treatment of their headaches prior. Subjects then randomly received either placebo or actual pulsed electromagnetic field therapy applied to their inner thighs for 1 hour per day, 5 days per week, for 2 weeks. After exposure, all subjects kept a 1-month follow up log.

Results of PEMF Study for Migraine Benefits

In the first month of follow-up:

  1. 73% of those who received actual treatment reported decreased headaches.

Of them:

  • 45% reported good decrease
  • 14% reported excellent decrease
  1. Verses the placebo group:

Which reported:

  • 15% worse
  • 20% good
  • 0% excellent

10 out of the 22 who received actual treatment received an additional 2 weeks of exposure after the initial 1-month follow-up. All continued to report decreased headache activity:

  • 50% good
  • 38% excellent
Studies utilizing pulsed electromagnetic field therapy see benefits.

13 individuals from the same group that received actual treatment elected not to continue treatment.

  • 12 showed decreased headache activity by the second month.
  • 29% good
  • 43% excellent

8 of the placebo subjects elected to receive 2 weeks of actual exposure after the initial 1-month follow up.

  • 75% showed decreased headache activity
  • 38% good
  • 38% excellent

In conclusion, the study reported that exposure of the inner thighs to pulsed electromagnetic field therapy for at least three weeks was an effective, short-term intervention for migraine, but not tension headaches. 

While there is no FDA approval for migraines, there are people utilizing Magnawaving for migraines, and there are studies utilizing pulsed electromagnetic field therapy seeing benefits.

Sources

https://www.ncbi.nlm.nih.gov/m/pubmed/11279973/